⌕
Resmed · RMD · NYSE
Tenet 65 · Solid
Compare
$238.93−0.25%At closeTenet 65 · Solid
$238.93−0.60 (−0.25%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$238.96+0.03 (+0.01%)
After hours: Nov 16, 2026, 6:56 PM ET

Resmed (RMD) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 9, 2026 · 21:11 ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).

NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of ResMed Inc. (NYSE: RMD) concerning possible breaches of fiduciary duties. If you are a current shareholder of RM…

● Defense WorldNov 6, 2026 · 02:15 ETEARNINGS EXPECTED BY JAN 27
ResMed (NYSE:RMD) vs. Terumo (OTCMKTS:TRUMY) Financial Comparison

ResMed (NYSE: RMD - Get Free Report) and Terumo (OTCMKTS:TRUMY - Get Free Report) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of …

● BarronsNov 5, 2026 · 08:00 ET
Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain

ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.…

● Seeking AlphaNov 5, 2026 · 02:52 ET
Top 10 High Growth Dividend Stocks For November 2026

I present 10 high-quality dividend growth stocks with strong total return potential, screened for robust fundamentals and attractive valuations as of November 2026. Key criteria include Investment Score ≥70, future retur…

● The Motley FoolNov 2, 2026 · 04:13 ETEARNINGS EXPECTED BY JAN 27
ResMed: 3 Key Takeaways for Long-Term Investors

ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.…

● Zacks Investment ResearchOct 30, 2026 · 10:31 ETEARNINGS EXPECTED BY JAN 27
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the …

● Zacks Investment ResearchOct 30, 2026 · 08:30 ETEARNINGS EXPECTED BY JAN 27
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.…

● MarketBeatOct 30, 2026 · 07:15 ETEARNINGS EXPECTED BY JAN 27
What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care …

● Seeking AlphaOct 29, 2026 · 20:58 ETEARNINGS EXPECTED BY JAN 27
ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript

ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript…

● Zacks Investment ResearchOct 29, 2026 · 18:36 ETEARNINGS EXPECTED BY JAN 27
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates

ResMed (RMD) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.67 per share. This compares to earnings of $2.55 per share a year ago.…

● BenzingaOct 29, 2026 · 17:46 ETEARNINGS EXPECTED BY JAN 27
ResMed Q1 2027 Earnings Call Transcript

ResMed (NYSE:RMD) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.…

● GlobeNewsWireOct 29, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 27
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com…

● Zacks Investment ResearchOct 29, 2026 · 10:46 ET
Here's Why ResMed (RMD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

● Zacks Investment ResearchOct 28, 2026 · 10:16 ETEARNINGS EXPECTED BY JAN 27
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2…

● Zacks Investment ResearchOct 23, 2026 · 13:11 ETEARNINGS EXPECTED BY JAN 27
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.…

● Zacks Investment ResearchOct 23, 2026 · 09:56 ETEARNINGS EXPECTED BY JAN 27
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?

RMD heads into Q1 fiscal 2027 earnings with sleep device demand and new product launches supporting growth, while MatrixCare's divestiture weighs on revenues.…

● Zacks Investment ResearchOct 22, 2026 · 11:06 ETEARNINGS EXPECTED BY JAN 27
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 19, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40…

● Defense WorldOct 11, 2026 · 05:39 ET
ResMed (NYSE:RMD) CEO Sells $1,129,613.03 in Stock

ResMed Inc. (NYSE: RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the business's stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a t…

● GlobeNewsWireOct 1, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 27
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, aft…

● Defense WorldSep 22, 2026 · 06:03 ETEARNINGS EXPECTED BY JAN 27
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in s…

● Defense WorldSep 17, 2026 · 04:13 ETEARNINGS EXPECTED BY JAN 27
Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD

Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 sh…

● PRNewsWireSep 3, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).…

● PRNewsWireAug 27, 2026 · 16:15 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).  Such investors are advised to contact Danielle Peyton at newac…

● GlobeNewsWireAug 27, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan…

● GlobeNewsWireAug 17, 2026 · 16:10 ETCOMPANY'S OWN WORDS
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lea…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Jan 27. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just RMD · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.